Remember
 
 
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.
     
 

Friday, September 29, 2017

SpeculatingStocks.com Stock Pick



Stock Price: $3.75

Champions Oncology, Inc. is engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs.

CSBR has a technology dubbed "The Champions TumorGraft" that uniquely analyzes a patient's tumor based on its distinct set of molecular changes. This enables oncologists to create a personalized treatment for the patient and can be a powerful tool in extending a patient's life. Champions Oncology TumorGraft technology has engrafted 900+ tumors. Oncologists have been working directly with Champions Oncology. CSBR is proving out their TumorGraft technology.


The company also has research solutions, an area of their business that just received a $2 million contract with the National Cancer Institute. Not a bad accomplishment for a company worth just over $40 million right now. CSBR had revenue last year of $15.41 million, and reported record quarterly revenue of $5 million last quarter, a 37% Y-o-Y increase, on operating costs of $5.7 million. CSBR expects fiscal year 2018 revenue to come in at least 20% greater than 2017, which would put CSBR fiscal 2018 revenue at least at approximately $18.5 million.

CSBR's underlying fundamentals are improving and their foundation is not bad with the company getting closer to profitability. CSBR has no short term or long term debt as of last quarter on their balance sheet.

CSBR has seen an increase in volume the last two months, so it is slowly becoming discovered. CSBR has climbed from around $2.50 to as high as $4.37 since late-August. This trend can realistically continue as the company continues to progress and as investors continue to discover CSBR.

Speculative Score: 4

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

 
     
Untitled Document